The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

Weil, Gotshal & Manges LLP

Work +1 212 310 8000
Fax +1 212 310 8007

Jeffrey Osterman

Work +1 212 310 8155
Weil, Gotshal & Manges LLP


Jeffrey Osterman concentrates on matters with deep commercial or technical complexity and has had extensive experience with pharmaceutical transactions, technology transfer, outsourcing, technology integration, and merchandising. His clients include Eli Lilly, Sanofi, Softbank and Verizon. His areas of specialty range from treatment of intellectual property in bankruptcy to analysis of open source software issues. Mr. Osterman practiced in Japan for a year on secondment to Panasonic and regularly handles cross-border matters for clients both inside and outside the US.


Cornell University (BA, 1992); Harvard Law School (JD, 1995).

United States: Industry focus

Healthcare: life sciences

Within: Healthcare: life sciences

Weil, Gotshal & Manges LLP focuses on corporate matters and litigation with a ‘deep understanding of both the technology and the law’ and the ability to ‘plan appropriately and communicate effectively’. Practice co-head Elizabeth Weiswasser advised Sanofi on a bench trial in the client’s patent litigation infringement case against Merck, involving Sanofi’s insulin biologic blockbuster Lantus Solostar. Jeffrey Osterman, Michael Aiello and Jackie Cohen have been assisting Avista with its acquisition of regenerative medicine developer Organogenesis. Silicon Valley-based co-head Edward Reines and Derek Walter, who was made partner in 2018, are ‘the ultimate professionals’, and Michael Epstein is renowned for his technology and IP transaction expertise. Named individuals are based in New York unless otherwise indicated.

[back to top]

United States: Intellectual property

Patents: licensing

Within: Patents: licensing

Weil, Gotshal & Manges LLP provides comprehensive service on licensing matter, including due diligence in relation to M&A and joint ventures, research and development agreements and outsourcing agreements. On the life sciences side, the group recently advised Eli Lilly on the licensing aspects of its collaboration with Dicerna Pharmaceuticals, which aimed at using the latter's technology platform to discover and commercialize new medicines for cardio-metabolic disease, neurodegeneration and pain. A recent technology highlight was advising Facebook subsidiary Oculus on several strategic commercial agreements regarding Oculus' virtual reality products. Atos, The Campbell Soup Company and Sanofi are also clients. Practice head Michael Epstein, Jeffrey Osterman and Charan Sandhu in New York, and Silicon Valley's Karen Ballack form the heart of the practice.

[back to top]

United States: Media, technology and telecoms

Technology transactions

Within: Technology transactions

Weil, Gotshal & Manges LLP regularly handles technology and IP acquisitions and disposals, outsourcing transactions and licensing and development agreements. New York-based Jeffrey Osterman advised Sanofi on the technology and IP aspects of its $11.6bn acquisition of Bioverativ, a company involved in the treatment of blood disorders. Further, practice head Michael Epstein, also based in New York, advised The Campbell Soup Company on its $6.1bn acquisition of Snyder’s Lance – a manufacturer and marketer of snack food products. Other M&A-related technology transactions included assisting the chemical distributor Nexeo Solutions with its $2bn sale to Univar, a distributor of specialty chemical products.

[back to top]

Back to index

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to